J&J eyes US nod for Caplyta in bipolar mania after second trial win

Johnson & Johnson said a second late-stage study found its drug Caplyta reduced manic symptoms in adults with bipolar I disorder more than a placebo. Over three weeks, patients taking the 42-milligram daily dose had a greater average improvement, and nearly 44% saw symptoms improve by at least half, compared with about 24% on placebo. The results support a planned U.S. regulatory filing, Reuters reported.